

Annex I

List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 20 mg Spritzampullen	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 40 mg Spritzampullen	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 60 mg Spritzampullen	60 mg	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 80 mg Spritzampullen	80 mg	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg Spritzampullen	100 mg	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 120 mg Spritzampullen	120 mg	Solution for injection	Subcutaneous use	0.8 ml (150 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 150 mg Spritzampullen	150 mg	Solution for injection	Subcutaneous use	1 ml (150 mg/ml)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg/ml Durchstichflasche	300 mg	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg/1 ml Ampullen	100 mg	Solution for injection	Subcutaneous use; Intravenous use	100 mg / 1,0 ml
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 100 mg/10 ml Stechampullen	100 mg	Solution for injection	Extracorporeal use	100 mg / 10 ml
Austria	sanofi-aventis GmbH, Leonard-Bernstein-Straße 10, A-1220 Vienna, Austria	Lovenox 10 x 40 mg Pen	40 mg	Solution for injection	Subcutaneous use	400,00 mg/3 ml (equiv. 10 single doses of 40 mg)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	20 mg/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	40 mg/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use	0.4 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	60 mg/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	80 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	100 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	120 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (150 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Belgium	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	300 mg/3 ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	60 mg /0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	80 mg /0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml)
Bulgaria	SANOFI BULGARIA EOOD 90 Tsarigradsko chaussee Blvd. Office building Capital Fort, section A, 10th floor Sofia 1784, Bulgaria	Clexane	300 mg /3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzelova 70, 10000 Zagreb, Croatia	Clexane 2000 IU anti-Xa/0,2 ml otopina za injekciju u napunjenoj štrcaljki	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzelova 70, 10000 Zagreb, Croatia	Clexane 4000 IU anti-Xa/0,4 ml otopina za injekciju u napunjenoj štrcaljki	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzelova 70, 10000 Zagreb, Croatia	Clexane 6000 IU anti-Xa/0,6 ml otopina za injekciju u napunjenoj štrcaljki	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 8000 IU anti-Xa/0,8 ml otopina za injekciju u napunjenoj štrcaljki	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 10 000 IU anti-Xa/1,0 ml otopina za injekciju u napunjenoj štrcaljki	10 000 anti-Xa IU/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Croatia	sanofi-aventis Croatia d.o.o. Heinzlova 70, 10000 Zagreb, Croatia	Clexane 30 000 IU anti-Xa/3,0 ml otopina za injekciju u višedoznom spremniku	30 000 anti-Xa IU/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use	0.4 ml; (100 mg/ml equivalent to 10000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Cyprus	Sanofi-aventis Cyprus Ltd. 14, Charalambou Mouskou Strovolos, 2015 Nicosia Cyprus	Clexane	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Czech Republic	sanofi-aventis, s.r.o. Evropská 846/176a 160 00 Praha 6 Czech Republic	Clexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Czech Republic	sanofi-aventis, s.r.o. Evropská 846/176a 160 00 Praha 6 Czech Republic	Clexane Forte	150 mg/ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml; 1.0 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Denmark	sanofi-aventis Denmark A/S Slotsmarken 13 2970 Hørsholm Denmark	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Denmark	sanofi-aventis Denmark A/S Slotsmarken 13 2970 Hørsholm Denmark	Klexane	100 mg/ml	Solution for injection	Subcutaneous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Estonia	sanofi-aventis Estonia OÜ Pärnu mnt. 139 E/2 11317 Tallinn, Estonia	Clexane	10 000 anti-Xa IU/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml equivalent to 10000 anti-Xa IU/ml)
Finland	Sanofi Oy Huopalahdentie 24 00350 Helsinki Finland	Klexane	100 mg/ml	Solution for injection	Subcutaneous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Finland	Sanofi Oy Huopalahdentie 24 00350 Helsinki Finland	Klexane Cum Conservans	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml; 10 ml (100 mg/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 2000 UI anti-Xa/0,2 ml, solution injectable en seringue préremplie	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 4000 UI anti-Xa/0,4 ml, solution injectable en seringue préremplie	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 6000 UI anti-Xa/0,6 ml, solution injectable en seringue préremplie	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 8000 UI anti-Xa/0,8 ml, solution injectable en seringue préremplie	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 10 000 UI anti-Xa/1 ml, solution injectable en seringue préremplie	10 000 anti-Xa IU/1 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	LOVENOX 30 000 UI Anti-Xa/3 ml, solution injectable en flacon multidose	30 000 anti-Xa IU/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 2000 UI anti-Xa/0,2 ml, solution injectable en seringue préremplie	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 4000 UI anti-Xa/0,4 ml, solution injectable en seringue préremplie	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 6000 UI anti-Xa/0,6 ml, solution injectable en seringue préremplie	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 8000 UI anti-Xa/0,8 ml, solution injectable en seringue préremplie	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
France	Sanofi-aventis France 82 avenue Raspail 94250 Gentilly FRANCE	ENOXAPARINE SANOFI 10 000 UI anti-Xa/1 ml, solution injectable en seringue préremplie	10 000 anti-Xa IU/1 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 20mg	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 20 mg Klinik	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 20 mg Praxis	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 20 mg	20 mg	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 40 mg	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 40 mg Praxis	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 40 mg Klinik	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 40 mg	40 mg	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 60 mg	60 mg	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 60 mg Fertigspritzen	60 mg	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 80 mg	80 mg	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 80 mg Fertigspritzen	80 mg	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi 100 mg	100 mg	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane 100 mg Fertigspritzen	100 mg	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Enoxaparin Sanofi multidose 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane multidose 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Clexane Multidose 100 mg/ml Praxis	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Qualiop multidose 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Germany	Sanofi-Aventis Deutschland GmbH Industriepark Höchst Gebäude K703 65926 Frankfurt am Main Germany	Qualiop Klinik 100 mg/ml	100 mg/ml	Solution for injection	Subcutaneous use; Extracorporeal use	3 ml; 5 ml; 10 ml (100 mg/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	2000 anti-Xa IU /0.2 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	4000 anti-Xa IU /0.4 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	6000 anti-Xa IU /0.6 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	8000 anti-Xa IU /0.8 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	12000 anti-Xa IU /0.8 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	0.8 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Greece	sanofi-aventis AEBE 348, Syngrou Av. - Building A, 176 74 Kallithea – Athens Greece	Clexane	15000 anti-Xa IU /1.0 ml	Solution for injection	Subcutaneous use Intravenous use; Extracorporeal use	1 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	20 mg (2000 NE /0.2 ml)	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	40 mg (4000 NE /0.4 ml)	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	60 mg (6000 NE /0.6 ml)	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	80 mg (8000 NE /0.8 ml)	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	100 mg (10 000 NE/1 ml)	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane	300 mg (30 000 NE/3 ml)	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane Forte	120 mg/0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (150 mg/ml)
Hungary	SANOFI-AVENTIS Zrt. 1045. BUDAPEST TÓ U. 1-5 Hungary	Clexane Forte	150 mg/1.0 ml	Solution for injection	Subcutaneous use	1.0 ml (150 mg/ml)
Iceland	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Iceland	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)
Ireland	Sanofi-aventis Ireland Ltd T/A SANOFI Citywest Business Campus Dublin 24 Ireland	Clexane Syringes	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Ireland	Sanofi-aventis Ireland Ltd T/A SANOFI Citywest Business Campus Dublin 24 Ireland	Clexane Forte Syringe	150 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml; 1 ml (150 mg/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	10 000 anti-Xa IU/1.0 ml	Solution for injection	Subcutaneous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Italy	Sanofi S.p.A. Viale L. Bodio 37/b 20158 Milan, Italy	Clexane T	30 000 anti-Xa IU/3.0 ml	Solution for injection	Intravenous use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 2000 anti-Xa SV/0,2 ml šķīdums injekcijām pilnšļircē	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 4000 anti-Xa SV/0,4 ml šķīdums injekcijām pilnšļircē	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 6000 anti-Xa SV/0,6 ml šķīdums injekcijām pilnšļircē	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Latvia	sanofi – aventis Latvia SIA 33 - 8 Kr. Valdemāra Street Rīga, LV - 1010 Latvia	Clexane 8000 anti-Xa SV/0,8 ml šķīdums injekcijai pilnšļircē	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB “SANOFI-AVENTIS LIETUVA” A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 2 000 anti- Xa TV/0,2 ml injekcinis tirpalas užpildytame švirkšte	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 4 000 anti- Xa TV/0,4 ml injekcinis tirpalas užpildytame švirkšte	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 6 000 anti- Xa TV/0,6 ml injekcinis tirpalas užpildytame švirkšte	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 8 000 anti- Xa TV/0,8 ml injekcinis tirpalas užpildytame švirkšte	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Lithuania	UAB "SANOFI-AVENTIS LIETUVA" A.Juozapaviciaus 6/2, LT-09310 Vilnius, Lithuania	Clexane 10 000 anti- Xa TV/1,0 ml injekcinis tirpalas užpildytame švirkšte	10 000 anti-Xa IU/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	20 mg/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	40 mg/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use	0.4 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	60 mg/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	80 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	100 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	120 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use	0.8 ml (150 mg/ml)
Luxembourg	Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem, Belgium	Clexane	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	2000 anti-Xa IU /0.2 ml (20 mg/0.2 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	4000 anti-Xa IU /0.4 ml (40 mg/0.4 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	6000 anti-Xa IU /0.6 ml (60 mg/0.6 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	8000 anti-Xa IU /0.8 ml (80 mg/0.8 ml)	Solution for Injection	Subcutaneous use; Intravenous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane	10 000 anti-Xa IU /1.0 ml (100 mg/1 ml)	Solution for Injection	Subcutaneous use; Intravenous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane Forte Syringes	120 mg/0.8 ml	Solution for Injection	Subcutaneous use; Intravenous use	0.8 ml (150 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane Forte Syringes	150 mg/1.0 ml	Solution for Injection	Subcutaneous use; Intravenous use	1 ml (150 mg/ml)
Malta	Sanofi Malta Ltd 3 rd Floor, Avantech Building, St.Julian's Road, San Gwann SGN 2805, Malta	Clexane Multidose vial	30 000 anti-Xa IU /3.0 ml (300 mg/3 ml)	Solution for Injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Netherlands	sanofi-aventis Netherlands B.V. Kampenringweg 45 D-E 2803 PE Gouda The Netherlands	Clexane 100 mg/ml	100 mg/ml	Solution for Injection	Subcutaneous use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Netherlands	sanofi-aventis Netherlands B.V. Kampenringweg 45 D-E 2803 PE Gouda The Netherlands	Clexane 300 mg/3 ml	300 mg/ 3ml	Solution for Injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Netherlands	sanofi-aventis Netherlands B.V. Kampenringweg 45 D-E 2803 PE Gouda The Netherlands	Clexane 150 mg/ml	150 mg/ml	Solution for Injection	Subcutaneous use	0.8 ml; 1.0 ml (150 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Norway	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	100 mg/ml	Solution for Injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Norway	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	100 mg/ml	Solution for Injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)
Norway	Sanofi-aventis Norge AS P.O.Box 133 1325 Lysaker Norway	Klexane	150 mg/ml	Solution for Injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml; 1.0 ml (150 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	20 mg /0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	40 mg /0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	60 mg /0.6 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.6 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	80 mg /0.8 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	100 mg /1 ml	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (100 mg/ml)
Poland	Sanofi-Aventis France 82, Avenue Raspail 94250 Gentilly France	Clexane	300 mg /3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)
Poland	Aventis Pharma Limited One Onslow Street Guildford, Surrey GU1 4YS United Kingdom	Clexane forte	120 mg /0.8 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (150 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Poland	Aventis Pharma Limited One Onslow Street Guildford, Surrey GU1 4YS United Kingdom	Clexane forte	150 mg /1 ml	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (150 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	100 mg/1 ml	Solution for injection	Subcutaneous use	1 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	150 mg/1 ml	Solution for injection	Subcutaneous use	1 ml (150 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	80 mg/ 0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	60 mg/ 0.6 ml	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	40 mg/ 0.4 ml	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	20 mg/ 0.2 ml	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml)
Portugal	Sanofi – Produtos Farmacêuticos, Lda. Empreendimento Lagoas Park, Edifício 7 – 3º Piso 2740-244 Porto Salvo Portugal	Lovenox	120 mg/ 0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (120 mg/ml)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Romania	Sanofi Romania SRL, Strada Gara Herăstrău, nr. 4, Clădirea B, etajele 8-9, Sector 2, București, Romania	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	10 000 anti-Xa IU/1 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane	30 000 anti-Xa IU/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane forte	12000 anti-Xa IU /0.8 ml	solution for injection	Subcutaneous use	0.8 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Slovak Republic	sanofi-aventis Slovakia s.r.o. Einsteinova 24, 85101 Bratislava Slovak Republic	Clexane forte	15000 anti-Xa IU /1.0 ml	solution for injection	Subcutaneous use	1 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	2000 anti-Xa IU/0.2 ml	Solution for injection	Subcutaneous use	0.2 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	4000 anti-Xa IU/0.4 ml	Solution for injection	Subcutaneous use	0.4 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	6000 anti-Xa IU/0.6 ml	Solution for injection	Subcutaneous use	0.6 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	8000 anti-Xa IU/0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	10 000 anti-Xa IU/1 ml	Solution for injection	Subcutaneous use	1 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	10 000 anti-Xa IU/ml	Solution for injection	Subcutaneous use; Intravenous use	3 ml (100 mg/ml equivalent to 10 000 anti-Xa IU/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	12000 anti-Xa IU /0.8 ml	Solution for injection	Subcutaneous use	0.8 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Slovenia	sanofi-aventis d.o.o. Letališka 29 A 1000 Ljubljana Slovenia	Clexane	15000 anti-Xa IU /1 ml	Solution for injection	Subcutaneous use	1 ml (150 mg/ml equivalent to 15000 anti-Xa IU/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 20 mg (2.000 UI) solución inyectable en jeringa precargada	20 mg (2000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 40 mg (4.000 UI) solución inyectable en jeringa precargada	40 mg (4000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.4 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 60 mg (6.000 UI) solución inyectable en jeringa precargada	60 mg (6000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 80 mg (8.000 UI) solución inyectable en jeringa precargada	80 mg (8000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 100 mg (10.000 UI) solución inyectable en jeringa precargada	100 mg (10 000 IU)	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 120 mg (12.000 UI) solución inyectable en jeringa precargada	120 mg (12000 IU)	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (150 mg/ml)
Spain	sanofi-aventis, S.A. C/ Josep Pla, 2 08019 Barcelona Spain	Clexane 150 mg (15.000 UI) solución inyectable en jeringa precargada	150 mg (15000 IU)	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (150 mg/ml)
Sweden	Sanofi AB Box 30052 104 25 Stockholm Sweden	Klexane	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.2 ml; 0.4 ml; 0.6 ml; 0.8 ml; 1.0 ml (100 mg/ml)
Sweden	Sanofi AB Box 30052 104 25 Stockholm Sweden	Klexane (med konserveringsmedel)	100 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml; 10 ml (100 mg/ml)
Sweden	Sanofi AB Box 30052 104 25 Stockholm Sweden	Klexane	150 mg/ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml; 0.8 ml; 1.0 ml (150 mg/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	20 mg/ 0.2 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.2 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	40 mg /0.4 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.4 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	60 mg/0.6 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.6 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	80 mg/0.8 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	0.8 ml (100 mg/ml equivalent to 10 000 IU anti-Xa activity/ml)

Member State EU/EEA	Marketing authorisation holder company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Syringes	100 mg/1.0 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	1 ml (100 mg/ml equivalent to 10000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Forte Syringes	120 mg/0.8 ml	Solution for injection	Subcutaneous use; Extracorporeal use	0.8 ml (150 mg/ml equivalent to 15000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Forte Syringes	150 mg/1.0 ml	Solution for injection	Subcutaneous use; Extracorporeal use	1 ml (150 mg/ml equivalent to 15000 IU anti-Xa activity/ml)
United Kingdom	Aventis Pharma Limited One Onslow Street Guildford Surrey GU1 4YS United-Kingdom	Clexane Multidose vial	300 mg/3 ml	Solution for injection	Subcutaneous use; Intravenous use; Extracorporeal use	3 ml (100 mg/ml)